The No Pain Act will mandate Medicare insurance coverage for non-opioid pain management, including evidence-based treatments, ...

Two decades ago, when two genetic mutations were discovered in Asia that gave scientists a better idea of how pain sensations ...

Vertex Pharmaceuticals beat Wall Street's third-quarter expectations, but the real story for Vertex stock is still to come, analysts said Tuesday.Please watch the video at Investors.com - How To Buy ...

There is a tendency to overlook the multiple factors and stakeholders that contributed to the Rx opioid crisis. This includes ...

Opioids have long been used to treat severe pain, though their use in the management of chronic pain remains somewhat controversial. Some people can tolerate opioids for years without any adverse ...

Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...

An overview of federal and state laws and legal issues impacting physicians, non-physician practitioners (NPPs), and health ...

Over the past decade, perceptions of using opioids and cannabis for pain relief have changed significantly. The ongoing ...

Pacira ended the third quarter of 2024 with cash, cash equivalents and available-for-sale investments (“cash”) of $453.8 million. Cash provided by operations was $53.9 million in the third quarter of ...

Coming off of a strong third quarter, Vertex Pharmaceuticals is nearing several important milestones, including the potential approvals of vanzacaftor triple in cystic fibrosis and the non-opioid ...

First came the good news. Non-cancer pain — this giant untested market that Purdue wanted to crack open — turned out to be a ...